LYPHF (Luye Pharma Group) EPS (Basic): $0.02 (TTM As of Dec. 2025)


LYPHF Luye Pharma Group Ltd LYPHF
58 GF Score
Price $0.20
GF Value $0.33
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Luye Pharma Group EPS (Basic)?

Luye Pharma Group LYPHF 58 EPS (Basic) is $0.02 as of Dec. 2025. GuruFocus rates LYPHF with a GF Score™ of 58/100 and a GF Value™ of $0.33 (Possible Value Trap). The stock has 5 warning signs investors should review.

Luye Pharma Group's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was $0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02.

Luye Pharma Group's EPS (Diluted) for the six months ended in Dec. 2025 was $0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02.

Luye Pharma Group's EPS without NRI for the six months ended in Dec. 2025 was $0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 0.02.

During the past 12 months, Luye Pharma Group's average EPS without NRIGrowth Rate was -17.20% per year. During the past 3 years, the average EPS without NRI Growth Rate was -20.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Luye Pharma Group's highest 3-Year average EPS without NRI Growth Rate was 42.20% per year. The lowest was -29.20% per year. And the median was -7.40% per year.

Luye Pharma Group  (OTCPK:LYPHF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Luye Pharma Group EPS (Basic) Related Terms

Luye Pharma Group EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Luye Pharma Group's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Luye Pharma Group EPS (Basic) Chart

Luye Pharma Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 0.03 0.02 0.02 0.02

Luye Pharma Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.00 0.01 0.01
LYPHF
58GF Score
Luye Pharma Group Ltd LYPHF
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Luye Pharma Group EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Luye Pharma Group's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(87.85-0)/3895.813
=0.02

Luye Pharma Group's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(43.426-0)/4029.955
=0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $0.02 mean?
Luye Pharma Group (LYPHF) has a EPS (Basic) of $0.02 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Luye Pharma Group and its competitors.
Is Luye Pharma Group's EPS (Basic) too high?
Luye Pharma Group's current EPS (Basic) is $0.02. Overall, Luye Pharma Group has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's EPS (Basic) compare to ZTS?
Luye Pharma Group's EPS (Basic) of $0.02 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Luye Pharma Group and its competitors. Luye Pharma Group's current EPS (Basic) is $0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (LYPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.33, compared to a current price of $0.20 — trading 38.2% below its estimated fair value. The current EPS (Basic) is $0.02. Luye Pharma Group's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Luye Pharma Group (LYPHF), the current EPS (Basic) is $0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Luye Pharma Group (LYPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued. The current stock price of $0.20 is trading 38.2% below its estimated GF Value™ of $0.33. GuruFocus considers Luye Pharma Group to be Possible Value Trap.

Key valuation signals for LYPHF:

  • EPS (Basic): $0.02
  • GF Value™: $0.33 vs. price of $0.20 (38.2% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the LYPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Luye Pharma Group Business Description

Other Exchanges 02186:Hong KongLUP:Germany
Address Hongqiao Road 1438, 22nd Floor, Gubei International Fortune Center II, Changning District, Shanghai, CHN
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
58GF Score

Get the complete analysis for LYPHF

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price
$0.33
GF Value